Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®
September 13, 2022 03:01 ET
|
Sight Sciences, Inc.
310-patient RCT designed to evaluate the superiority of TearCare® (device) vs Restasis® (drug) in patients with chronic dry eye disease is now fully enrolled6-Month efficacy results expected by Summer...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
September 02, 2022 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
August 25, 2022 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
August 23, 2022 08:03 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
August 16, 2022 08:01 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Sight Sciences Reports Second Quarter 2022 Financial Results
August 11, 2022 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
July 28, 2022 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors
July 19, 2022 16:26 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
May 31, 2022 08:00 ET
|
Sight Sciences, Inc.
Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucomaThese 12-month outcomes were also confirmed by results from a subset...
Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium
May 19, 2022 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve...